Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 383

1.

The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer.

Gruber ES, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, Jomrich G, Schoppmann SF, Gnant M, Tse W, Kenner L.

Cells. 2019 Oct 30;8(11). pii: E1357. doi: 10.3390/cells8111357.

2.

Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.

Papakonstantinou A, Hedayati E, Hellström M, Johansson H, Gnant M, Steger G, Greil R, Untch M, Moebus V, Loibl S, Foukakis T, Bergh J, Matikas A.

Acta Oncol. 2019 Oct 4:1-7. doi: 10.1080/0284186X.2019.1670353. [Epub ahead of print]

PMID:
31583943
3.

Challenges and Controversies in Breast Surgery.

Gnant M.

Breast Care (Basel). 2019 Aug;14(4):185-187. doi: 10.1159/000502134. Epub 2019 Aug 7. No abstract available.

4.

Breast cancer.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F.

Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. Review.

PMID:
31548545
5.

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E.

Lancet Oncol. 2019 Sep;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1. Epub 2019 Aug 8.

PMID:
31402321
6.

New evidence and hope for young patients with breast cancer.

Gnant M.

Eur J Cancer. 2019 Sep;118:166-168. doi: 10.1016/j.ejca.2019.06.007. Epub 2019 Jul 30. No abstract available.

PMID:
31374402
7.

Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.

Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B.

Ann Oncol. 2019 Aug 2. pii: mdz235. doi: 10.1093/annonc/mdz235. [Epub ahead of print]

PMID:
31373601
8.

Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.

Singer CF, Filipits M, Jahn SW, Abete L, Jakesz R, Greil R, Bauernhofer T, Kwasny W, Seifert M, Fitzal F, Kastner M, Schmitt M, Moinfar F, Gnant M.

Breast. 2019 Aug;46:101-107. doi: 10.1016/j.breast.2019.05.007. Epub 2019 May 3.

PMID:
31132475
9.

The 3-60 criteria challenge established predictors of postoperative mortality and enable timely therapeutic intervention after liver resection.

Gyoeri GP, Pereyra D, Braunwarth E, Ammann M, Jonas P, Offensperger F, Klinglmueller F, Baumgartner R, Holzer S, Gnant M, Laengle F, Staettner S, Gruenberger T, Starlinger P.

Hepatobiliary Surg Nutr. 2019 Apr;8(2):111-124. doi: 10.21037/hbsn.2019.02.01.

10.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2019 Jun;269(6):1163-1169. doi: 10.1097/SLA.0000000000002771.

PMID:
31082916
11.

Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M.

Clin Cancer Res. 2019 Jul 1;25(13):3865-3872. doi: 10.1158/1078-0432.CCR-19-0376. Epub 2019 May 7.

PMID:
31064782
12.

Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma.

Gruber ES, Jomrich G, Tamandl D, Gnant M, Schindl M, Sahora K.

PLoS One. 2019 May 6;14(5):e0215915. doi: 10.1371/journal.pone.0215915. eCollection 2019.

13.

Denosumab in early-stage breast cancer - Authors' reply.

Gnant M, Pfeiler G, Frantal S; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 May;20(5):236. doi: 10.1016/S1470-2045(19)30228-1. No abstract available.

PMID:
31044698
14.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M.

Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30.

15.

Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection.

Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, Schindl M.

J Gastrointest Surg. 2019 Mar 28. doi: 10.1007/s11605-019-04187-z. [Epub ahead of print]

PMID:
30923999
16.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J 2nd, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A.

Breast Cancer Res. 2019 Mar 11;21(1):39. doi: 10.1186/s13058-019-1115-2.

17.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

PMID:
30795951
18.

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).

Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL.

Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5.

PMID:
30723140
19.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipović S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M.

Ann Oncol. 2019 Apr 1;30(4):567-574. doi: 10.1093/annonc/mdz016.

PMID:
30689703
20.

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Clin Cancer Res. 2019 May 1;25(9):2737-2744. doi: 10.1158/1078-0432.CCR-18-1968. Epub 2019 Jan 15.

PMID:
30647078
21.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 .

Ann Oncol. 2019 Jul 1;30(7):1181. doi: 10.1093/annonc/mdy537. No abstract available.

22.

• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.

Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group.

Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11.

23.

Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.

Henke G, Knauer M, Ribi K, Hayoz S, Gérard MA, Ruhstaller T, Zwahlen DR, Muenst S, Ackerknecht M, Hawle H, Fitzal F, Gnant M, Mátrai Z, Ballardini B, Gyr A, Kurzeder C, Weber WP.

Trials. 2018 Dec 4;19(1):667. doi: 10.1186/s13063-018-3021-9.

24.

The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.

Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mislej EM, Stabuc B, Gnant M, Bachleitner-Hofmann T, Roth W, Scherer D, Haefeli WE, Ulrich CM, DeCensi A.

BMC Cancer. 2018 Dec 4;18(1):1210. doi: 10.1186/s12885-018-5126-7.

25.

ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.

Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M, Mazel M, Cayrefourcq L, Geraci S, Vacher S, Pantano F, Filipits M, Driouch K, Bieche I, Gnant M, Jacot W, Aubin JE, Duterque-Coquillaud M, Alix-Panabières C, Clézardin P, Bonnelye E.

Oncogene. 2019 Feb;38(7):950-964. doi: 10.1038/s41388-018-0579-3. Epub 2018 Nov 26.

PMID:
30478447
26.

Delta albumin is a better prognostic marker for complications following laparoscopic intestinal resection for Crohn's disease than albumin alone - A retrospective cohort study.

Müller C, Stift A, Argeny S, Bergmann M, Gnant M, Marolt S, Unger L, Riss S.

PLoS One. 2018 Nov 13;13(11):e0206911. doi: 10.1371/journal.pone.0206911. eCollection 2018.

27.

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.

Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, Steger GG, Untch M, Johansson H, Hellström M, Malmström P, Gnant M, Loibl S, Bergh J.

Ann Oncol. 2019 Jan 1;30(1):109-114. doi: 10.1093/annonc/mdy475.

PMID:
30357310
28.

Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.

Meisel JL, Venur VA, Gnant M, Carey L.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:78-86. doi: 10.1200/EDBK_201037. Review.

PMID:
30231395
29.

Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy.

Weber WP, Haug M, Kurzeder C, Bjelic-Radisic V, Koller R, Reitsamer R, Fitzal F, Biazus J, Brenelli F, Urban C, Paulinelli RR, Blohmer JU, Heil J, Hoffmann J, Matrai Z, Catanuto G, Galimberti V, Gentilini O, Barry M, Hadar T, Allweis TM, Olsha O, Cardoso MJ, Gouveia PF, Rubio IT, de Boniface J, Svensjö T, Bucher S, Dubsky P, Farhadi J, Fehr MK, Fulco I, Ganz-Blättler U, Günthert A, Harder Y, Hauser N, Kappos EA, Knauer M, Landin J, Mechera R, Meani F, Montagna G, Ritter M, Saccilotto R, Schwab FD, Steffens D, Tausch C, Zeindler J, Soysal SD, Lohsiriwat V, Kovacs T, Tansley A, Wyld L, Romics L, El-Tamer M, Pusic AL, Sacchini V, Gnant M.

Breast Cancer Res Treat. 2018 Dec;172(3):523-537. doi: 10.1007/s10549-018-4937-1. Epub 2018 Sep 4. Review.

30.

Toward a Consensus on Centralization in Surgery.

Vonlanthen R, Lodge P, Barkun JS, Farges O, Rogiers X, Soreide K, Kehlet H, Reynolds JV, Käser SA, Naredi P, Borel-Rinkes I, Biondo S, Pinto-Marques H, Gnant M, Nafteux P, Ryska M, Bechstein WO, Martel G, Dimick JB, Krawczyk M, Oláh A, Pinna AD, Popescu I, Puolakkainen PA, Sotiropoulos GC, Tukiainen EJ, Petrowsky H, Clavien PA.

Ann Surg. 2018 Nov;268(5):712-724. doi: 10.1097/SLA.0000000000002965.

PMID:
30169394
31.

TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.

Braunschmid T, Kührer I, Mittlböck M, Westerhoff M, Kappel-Latif S, Brammen L, Krishnadath KK, Phillips WA, Gnant M, Kandioler D.

Ann N Y Acad Sci. 2018 Dec;1434(1):46-53. doi: 10.1111/nyas.13947. Epub 2018 Aug 15. Review.

PMID:
30112858
32.

Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis.

Bhangu JS, Beer A, Mittlböck M, Tamandl D, Pulverer W, Schönthaler S, Taghizadeh H, Stremitzer S, Kaczirek K, Gruenberger T, Gnant M, Bergmann M, Mannhalter C, Weinhäusel A, Oehler R, Bachleitner-Hofmann T.

Ann Surg. 2018 Nov;268(5):894-902. doi: 10.1097/SLA.0000000000002901.

PMID:
30080722
33.

PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.

Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, Schoppmann SF.

Oncoimmunology. 2018 Mar 13;7(6):e1435226. doi: 10.1080/2162402X.2018.1435226. eCollection 2018.

34.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. No abstract available.

PMID:
29733336
35.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2018 Apr 24. doi: 10.1097/SLA.0000000000002771. [Epub ahead of print]

PMID:
29697452
36.

Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy.

Schindl M, Függer R, Götzinger P, Längle F, Zitt M, Stättner S, Kornprat P, Sahora K, Hlauschek D, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Br J Surg. 2018 Jun;105(7):811-819. doi: 10.1002/bjs.10840. Epub 2018 Apr 17.

37.

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):316-324. doi: 10.1016/j.ijrobp.2018.01.105. Epub 2018 Feb 6.

PMID:
29534902
38.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.

39.

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Strobl S, Wimmer K, Exner R, Devyatko Y, Bolliger M, Fitzal F, Gnant M.

Curr Treat Options Oncol. 2018 Mar 12;19(4):18. doi: 10.1007/s11864-018-0535-z. Review.

PMID:
29527635
40.

High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.

Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, Gnant M, Bachleitner-Hofmann T, Scherer D, Ulrich CM, Stabuc B, Puntoni M, Coccia G, Petrera M, Haefeli WE, DeCensi A.

Gastroenterology. 2018 Apr;154(5):1543-1545. doi: 10.1053/j.gastro.2017.12.040. Epub 2018 Mar 8. No abstract available.

41.

Optimal duration of adjuvant endocrine therapy: how to apply the newest data.

Wimmer K, Strobl S, Bolliger M, Devyatko Y, Korkmaz B, Exner R, Fitzal F, Gnant M.

Ther Adv Med Oncol. 2017 Nov;9(11):679-692. doi: 10.1177/1758834017732966. Epub 2017 Oct 27. Review.

42.

Explained variation in shared frailty models.

Gleiss A, Gnant M, Schemper M.

Stat Med. 2018 Apr 30;37(9):1482-1490. doi: 10.1002/sim.7592. Epub 2017 Dec 28.

PMID:
29282754
43.

A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.

Piringer G, Fridrik M, Fridrik A, Leiherer A, Zabernigg A, Greil R, Eisterer W, Tschmelitsch J, Lang A, Frantal S, Burgstaller S, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Support Care Cancer. 2018 Apr;26(4):1345-1352. doi: 10.1007/s00520-017-3961-8. Epub 2017 Nov 22.

PMID:
29168033
44.

Sized Influences Nodal Status in Women Aged #70 with Endocrine Responsive Breast Cancer.

Fitzal F, Helfgott R, Moinfar F, Gnant M.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):555-556. doi: 10.1245/s10434-017-6156-0. Epub 2017 Nov 20. No abstract available.

PMID:
29159741
45.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.

PMID:
29146401
46.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

47.

Inflammatory response and oxidative stress during liver resection.

Schwarz C, Fitschek F, Bar-Or D, Klaus DA, Tudor B, Fleischmann E, Roth G, Tamandl D, Wekerle T, Gnant M, Bodingbauer M, Kaczirek K.

PLoS One. 2017 Oct 18;12(10):e0185685. doi: 10.1371/journal.pone.0185685. eCollection 2017.

48.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308. Erratum in: Ann Oncol. 2018 Oct 1;29(10):2153. Ann Oncol. 2019 Jan 9;:.

49.

Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment.

Gnant M, Van Poznak C, Schnipper L.

Am Soc Clin Oncol Educ Book. 2017;37:116-122. doi: 10.14694/EDBK_177357. Review.

PMID:
28561722
50.

St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.

Gnant M, Harbeck N, Thomssen C.

Breast Care (Basel). 2017 May;12(2):102-107. doi: 10.1159/000475698. Epub 2017 Apr 26. Review.

Supplemental Content

Support Center